Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

 
• By Joseph Haas
  
SC2007_Moving_1094693954_1200.jpg
Bischofberger is jumpstarting R&D by bringing in compounds from his prior company
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business